文献速递关节外科

别急:延长口服抗生素预防不能降低关节置换术后90天感染率

Not so Fast: Extended Oral Antibiotic Prophylaxis Does Not Reduce 90-Day Infection Rate Following Joint Arthroplasty.
PubMed 文献 · J Arthroplasty · 2024-04-27

这项回顾性队列研究纳入2018至2022年单中心4576例初次全髋或全膝关节置换患者,比较接受与未接受延长口服抗生素预防者的90天和1年假体周围关节感染率。结果显示两组90天假体周围关节感染率无差异(延长口服抗生素组1% vs 无延长口服抗生素组0.8%,P=0.6),1年时仍无差异,高危亚组亦无统计学显著差异。作者因此不能推荐广泛采用延长口服抗生素预防。

要点

  • 延长口服抗生素预防组90天假体周围关节感染率为1%,无延长口服抗生素预防组为0.8%,两组无差异(P=0.6)。
  • 高危亚组中延长口服抗生素预防组假体周围关节感染率为0.8%,无延长口服抗生素预防组为2.3%,差异未达统计学显著(P=0.2)。
  • 两组艰难梭菌感染率均为0.1%(P>0.9),90天内感染假体周围关节感染者的抗生素耐药率分别为59%和83%(P=0.2)。

核心结论

  • 在可分析的样本量下,普遍应用延长口服抗生素预防与初次全髋或全膝关节置换术后假体周围关节感染风险降低无关。
  • 在高危患者中,延长口服抗生素预防与无延长口服抗生素预防相比,假体周围关节感染率无统计学显著差异。
  • 作者不能推荐广泛采用延长口服抗生素预防,且需要明确延长口服抗生素预防的作用,即使在高危患者中也是如此。

研究设计与样本

  • 回顾性队列研究,纳入2018年至2022年在单一机构接受初次全髋或全膝关节置换的4576例患者。
  • 自2020年起,本机构在全髋或全膝关节置换术后给予延长口服抗生素预防10天。
  • 根据是否接受术后延长口服抗生素预防分为两组:延长口服抗生素预防组1769例,无延长口服抗生素预防组2807例。
  • 比较两组90天和1年结局,重点为假体周围关节感染,并对高危患者进行亚组分析。

主要发现

  • 90天假体周围关节感染率两组无差异:延长口服抗生素预防组1% vs 无延长口服抗生素预防组0.8%(P=0.6)。
  • 1年假体周围关节感染率两组仍无显著差异:延长口服抗生素预防组1% vs 无延长口服抗生素预防组1%(P=0.9)。
  • 高危患者亚组分析显示术后假体周围关节感染率无差异:延长口服抗生素预防组(n=254)0.8% vs 无延长口服抗生素预防组(n=396)2.3%(P=0.2)。
  • 艰难梭菌感染发生率无差异:延长口服抗生素预防组0.1% vs 无延长口服抗生素预防组0.1%(P>0.9)。
  • 90天内发生假体周围关节感染者中抗生素耐药率无差异:延长口服抗生素预防组59% vs 无延长口服抗生素预防组83%(P=0.2)。

关键数值与推荐

  • 90天假体周围关节感染率:延长口服抗生素预防组1% vs 无延长口服抗生素预防组0.8%(P=0.6)。
  • 1年假体周围关节感染率:延长口服抗生素预防组1% vs 无延长口服抗生素预防组1%(P=0.9)。
  • 高危患者术后假体周围关节感染率:延长口服抗生素预防组(n=254)0.8% vs 无延长口服抗生素预防组(n=396)2.3%(P=0.2)。
  • 艰难梭菌感染发生率:延长口服抗生素预防组0.1% vs 无延长口服抗生素预防组0.1%(P>0.9)。
  • 90天内假体周围关节感染者的抗生素耐药率:延长口服抗生素预防组59% vs 无延长口服抗生素预防组83%(P=0.2)。

临床怎么用

  • 作者不能推荐广泛采用延长口服抗生素预防。
  • 作者认为需要明确延长口服抗生素预防的作用,即使在高危患者中也是如此。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Periprosthetic joint infection (PJI) is a devastating complication following both total hip (THA) and knee (TKA) arthroplasty. Extended oral antibiotic (EOA) prophylaxis has been reported to reduce PJI following TJA in high-risk patients. The purpose of this study was to determine if EOA reduces PJI in all-comers and high-risk THA and TKA populations. METHODS: This is a retrospective cohort study, including 4,576 patients undergoing primary THA or TKA at a single institution from 2018 to 2022. Beginning in 2020, EOA prophylaxis was administered for 10 days following THA or TKA at our institution. Patients were separated into 2 cohorts (1,769 EOA, 2,807 no EOA) based on whether they received postoperative EOA. The 90-day and 1-year outcomes, with a focus on PJI, were then compared between groups. A subgroup analysis of high-risk patients was also performed. RESULTS: There was no difference in 90-day PJI rates between cohorts (EOA 1 versus no EOA 0.8%; P = .6). The difference in the rate of PJI remained insignificant at 1 year (EOA 1 versus no EOA 1%; P = .9). Similarly, our subgroup analysis of high-risk patients demonstrated no difference in postoperative PJI between EOA (n = 254) and no EOA (n = 396) (0.8 versus 2.3%, respectively; P = .2). Reassuringly, we also found no differences in the incidence of Clostridium difficile infection (EOA 0.1 versus no EOA 0.1%; P > .9) or in antibiotic resistance among those who developed PJI within 90 days (EOA 59 versus no EOA 83%; P = .2). CONCLUSIONS: With the numbers available for analysis, EOA prophylaxis was not associated with PJI risk reduction following primary TJA when universally deployed. Furthermore, among high-risk patients, there was no statistically significant difference. While we did not identify increased antibiotic resistance or Clostridium difficile infection, we cannot recommend wide-spread adoption of EOA prophylaxis, and clarification regarding the role of EOA, even in high-risk patients, is needed.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Flynn JB, Yokhana SS, Wilson JM, et al. Not so Fast: Extended Oral Antibiotic Prophylaxis Does Not Reduce 90-Day Infection Rate Following Joint Arthroplasty. J Arthroplasty. 2024. PMID: 38685337. doi:10.1016/j.arth.2024.04.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。